Abstract
Objective
Prior studies of vision-related quality of life (VRQoL) have examined advanced age-related macular degeneration (AMD) as a single group or focused on neovascular AMD (nAMD), even though advanced AMD can refer to either central geographic atrophy (GA) or nAMD. We compared the natural progression of VRQoL in central GA versus nAMD.
Methods
We included Age-Related Eye Disease Study (AREDS) participants with central GA (n = 206) or nAMD (n = 198) who completed the National Eye Institute Visual Function Questionnaire (NEI-VFQ) between 1997 and 2005. The rate of change of VRQoL was calculated as the slopes of linear models fit to longitudinal individual-level NEI-VFQ scores. Multivariable regressions identified factors associated with experiencing a decline in VRQoL during the study period and cross-sectional VRQoL score.
Results
There was a minor decline in VRQoL prior to the development of nAMD but a significantly steeper decline after progression to nAMD (0.49 ± 2.91 vs. 3.30 ± 5.58 NEI-VFQ units/year; p < 0.001). The rates of VRQoL decline were similar before and after the development of central GA (1.99 ± 4.97 vs. 1.68 ± 4.65 NEI-VFQ units/year; p = 0.66). Prior to the development of advanced AMD, the rate of VRQoL decline was greater for participants destined to develop central GA versus nAMD (p = 0.007), while postprogression to advanced disease, the rate was greater in nAMD compared with central GA (p = 0.012). Female gender (odds ratio [OR] 2.61, 95% confidence interval [CI] 1.38-5.06; p = 0.003) and higher baseline VRQoL score (OR 1.03, 95% CI 1.01–1.06; p = 0.006) were independently associated with experiencing a longitudinal decline in VRQoL.
Conclusion
The natural progression of VRQoL differed in central GA versus nAMD, both before and after the development of advanced disease, suggesting that future studies should consider separating these phenotypes. Females and those with a higher baseline VRQoL were more likely to experience a longitudinal decline in VRQoL following progression to advanced AMD.
Similar content being viewed by others
Availability of data and material
The Age-Related Eye Disease Study (AREDS) data are available upon request for authorized access: https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login.
References
Yuzawa M, Fujita K, Tanaka E, Wang EC (2013) Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice. Clin Ophthalmol (Auckland, NZ) 7:1325–1332. https://doi.org/10.2147/opth.S45248
Sadda SR, Chakravarthy U, Birch DG, Staurenghi G, Henry EC, Brittain C (2016) Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. Retina 36(10):1806–1822. https://doi.org/10.1097/IAE.0000000000001283
Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD (1998) Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol (Chicago, Ill : 1960) 116(11):1496–1504
Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI (1998) The psychosocial impact of macular degeneration. Arch Ophthalmol (Chicago, Ill : 1960) 116(4):514–520. https://doi.org/10.1001/archopht.116.4.514
Cahill MT, Banks AD, Stinnett SS, Toth CA (2005) Vision-related quality of life in patients with bilateral severe age-related macular degeneration. Ophthalmology 112(1):152–158. https://doi.org/10.1016/j.ophtha.2004.06.036
Dong LM, Childs AL, Mangione CM, Bass EB, Bressler NM, Hawkins BS, Marsh MJ, Miskala P, Jaffee HA, McCaffrey LA (2004) Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol 138(1):91–108. https://doi.org/10.1016/j.ajo.2004.02.011
Miskala PH, Hawkins BS, Mangione CM, Bass EB, Bressler NM, Dong LM, Marsh MJ, McCaffrey LD (2003) Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. Arch Ophthalmol (Chicago, Ill: 1960) 121(4):531–539. https://doi.org/10.1001/archopht.121.4.531
Clemons TE, Chew EY, Bressler SB, McBee W, Age-Related Eye Disease Study Research G (2003) National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol (Chicago, Ill: 1960) 121(2):211–217. https://doi.org/10.1001/archopht.121.2.211
Lindblad AS, Clemons TE (2005) Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report no. 14. Arch Ophthalmol (Chicago, Ill : 1960) 123(9):1207–1214. https://doi.org/10.1001/archopht.123.9.1207
Coleman AL, Yu F, Ensrud KE, Stone KL, Cauley JA, Pedula KL, Hochberg MC, Mangione CM (2010) Impact of age-related macular degeneration on vision-specific quality of life: follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. Am J Ophthalmol 150(5):683–691. https://doi.org/10.1016/j.ajo.2010.05.030
Ambati J, Fowler BJ (2012) Mechanisms of age-related macular degeneration. Neuron 75(1):26–39. https://doi.org/10.1016/j.neuron.2012.06.018
Kandasamy R, Wickremasinghe S, Guymer R (2017) New treatment modalities for geographic atrophy. Asia Pac J Ophthalmol (Phila) 6(6):508–513. https://doi.org/10.22608/APO.2017262
Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Quiroz-Mercado H, Mandava N (2014) Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. Retina 34(3):423–441. https://doi.org/10.1097/IAE.0000000000000036
Sivaprasad S, Tschosik E, Kapre A, Varma R, Bressler NM, Kimel M, Dolan C, Silverman D (2018) Reliability and construct validity of the NEI VFQ-25 in a subset of patients with geographic atrophy from the phase 2 Mahalo study. Am Jof Ophthalmol 190:1–8. https://doi.org/10.1016/j.ajo.2018.03.006
Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J, Vision Health Cost-Effectiveness Study G (2009) Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol (Chicago, Ill : 1960) 127(4):533–540. https://doi.org/10.1001/archophthalmol.2009.58
Age-Related Eye Disease Study Research G (1999) The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials 20(6):573–600
Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Davis MD, Ferris FL 3rd (2014) Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol 132(3):272–277. https://doi.org/10.1001/jamaophthalmol.2013.6636
Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, Fine JT, Bressler NM (2011) Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci 52(6):3354–3359. https://doi.org/10.1167/iovs.10-5645
National Center for Biotechnology Information (NCBI) database of Genotypes and Phenotypes (dbGaP) National Eye Institute (NEI) Age-Related Eye Disease Study (AREDS). dbGaP Study Accession: phs000001v3p1 2016. Bethesda: National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000001.v3.p1. Accessed 15 Nov 2019
Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, Klein R, Ferris FL, Bressler SB, Milton RC, Age-Related Eye Disease Study G (2005) The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (Chicago, Ill : 1960) 123(11):1484–1498. https://doi.org/10.1001/archopht.123.11.1484
Kong X, Strauss RW, Cideciyan AV, Michaelides M, Sahel JA, Munoz B, Ahmed M, Ervin AM, West SK, Cheetham JK, Scholl HPN, ProgStar Study G (2017) Visual acuity change over 12 months in the prospective progression of atrophy secondary to stargardt disease (ProgStar) study: ProgStar Report Number 6. Ophthalmology 124(11):1640–1651. https://doi.org/10.1016/j.ophtha.2017.04.026
Davis LJ, Schechtman KB, Wilson BS, Rosenstiel CE, Riley CH, Libassi DP, Gundel RE, Rosenberg L, Gordon MO, Zadnik K, Collaborative longitudinal evaluation of keratoconus study G (2006) Longitudinal changes in visual acuity in keratoconus. Invest Ophthalmol Vis Sci 47(2):489–500. https://doi.org/10.1167/iovs.05-0381
Shen LL, Sun M, Khetpal S, Grossetta Nardini HK, Del Priore LV (2020) Topographic variation of the growth rate of geographic atrophy in nonexudative age-related macular degeneration: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci 61(1):2. https://doi.org/10.1167/iovs.61.1.2
Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115(1):116–126. https://doi.org/10.1016/j.ophtha.2007.03.008
Eid M, Diener E (2004) Global judgments of subective well-being: situational variability and long-term stability. Soc Indic Res 65(3):245–277
Schippert AC, Jelin E, Moe MC, Heiberg T, Grov EK (2018) The impact of age-related macular degeneration on quality of life and its association with demographic data: results from the NEI VFQ-25 questionnaire in a Norwegian Population. Gerontol Geriatr Med 4:2333721418801601. https://doi.org/10.1177/2333721418801601
Chatziralli I, Mitropoulos P, Parikakis E, Niakas D, Labiris G (2017) Risk factors for poor quality of life among patients with age-related macular degeneration. Semin Ophthalmol 32(6):772–780. https://doi.org/10.1080/08820538.2016.1181192
Fink BA, Wagner H, Steger-May K, Rosenstiel C, Roediger T, McMahon TT, Gordon MO, Zadnik K (2005) Differences in keratoconus as a function of gender. Am J Ophthalmol 140(3):459–468. https://doi.org/10.1016/j.ajo.2005.03.078
Sorman DE, Ljungberg JK, Ronnlund M (2018) Reading habits among older adults in relation to level and 15-year changes in verbal fluency and episodic recall. Front Psychol 9:1872. https://doi.org/10.3389/fpsyg.2018.01872
Astarita C, D'Angelo-Maansson B, Massaro-Giordano M, Alba MP, Boffo S, Macchi I, Giordano A, Macaluso M (2018) Effect of sex steroid hormone fluctuations in the pathophysiology of male-retinal pigment epithelial cells. J Cell Physiol 233(9):6965–6974. https://doi.org/10.1002/jcp.26486
Zetterberg M (2016) Age-related eye disease and gender. Maturitas 83:19–26. https://doi.org/10.1016/j.maturitas.2015.10.005
Tufail A, Margaron P, Guerin T, Larsen M (2019) Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2018-313682
Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW, Macular Telangiectasia Research G (2008) The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. Invest Ophthalmol Vis Sci 49(10):4340–4346. https://doi.org/10.1167/iovs.08-1749
Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J, Ianchulev T, Marina GAR (2010) Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 117(4):747–756 e744. https://doi.org/10.1016/j.ophtha.2009.09.002
Ramírez Estudillo JA, León Higuera MI, Rojas Juárez S, Ordaz Vera ML, Pablo Santana Y, Celis Suazo B (2017) Visual rehabilitation via microperimetry in patients with geographic atrophy: a pilot study. Int J Retina Vitreous 3(1):21. https://doi.org/10.1186/s40942-017-0071-1
Nilsson UL, Frennesson C, Nilsson SE (2003) Patients with AMD and a large absolute central scotoma can be trained successfully to use eccentric viewing, as demonstrated in a scanning laser ophthalmoscope. Vision Res 43(16):1777–1787. https://doi.org/10.1016/s0042-6989(03)00219-0
Lamoureux EL, Pallant JF, Pesudovs K, Rees G, Hassell JB, Keeffe JE (2007) The effectiveness of low-vision rehabilitation on participation in daily living and quality of life. Invest Ophthalmol Vis Sci 48(4):1476–1482. https://doi.org/10.1167/iovs.06-0610
Nickels S, Schuster AK, Singer S, Wild PS, Laubert-Reh D, Schulz A, Finger RP, Michal M, Beutel ME, Münzel T, Lackner KJ, Pfeiffer N (2017) The National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) - reference data from the German population-based Gutenberg Health Study (GHS). Health Qual Life Outcomes 15(1):156. https://doi.org/10.1186/s12955-017-0732-7
van der Aa HP, Xie J, Rees G, Fenwick E, Holloway EE, van Rens GH, van Nispen RM (2016) Validated prediction model of depression in visually impaired older adults. Ophthalmology 123(5):1164–1166. https://doi.org/10.1016/j.ophtha.2015.11.028
Massof RW, Fletcher DC (2001) Evaluation of the NEI visual functioning questionnaire as an interval measure of visual ability in low vision. Vision Res 41(3):397–413. https://doi.org/10.1016/s0042-6989(00)00249-2
Revicki DA, Rentz AM, Harnam N, Thomas VS, Lanzetta P (2010) Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 51(2):712–717. https://doi.org/10.1167/iovs.09-3766
Owen CG, Rudnicka AR, Smeeth L, Evans JR, Wormald RP, Fletcher AE (2006) Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population? BMC Ophthalmol 6:24. https://doi.org/10.1186/1471-2415-6-24
Acknowledgments
The dataset used for the analyses described in this manuscript was obtained from the AREDS Database through dbGaP accession number phs000001.v3.p1. Funding support for AREDS was provided by the National Eye Institute (N01-EY-0-2127). We would like to thank the AREDS participants and the AREDS Research Group for their valuable contribution to this research.
Funding
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number T35AG049685 (Recipient: Ahluwalia) and P30 EY026878 from the National Eye Institute (NEI) (Recipient: Yale Vision Science Core).
Author information
Authors and Affiliations
Contributions
Conceptualization: Aneesha Ahluwalia, Liangbo L. Shen, and Lucian V. Del Priore; Methodology: Aneesha Ahluwalia, and Liangbo L. Shen; Formal analysis and investigation: Aneesha Ahluwalia; Writing—original draft preparation: Aneesha Ahluwalia; Writing—review and editing: Aneesha Ahluwalia, Liangbo L. Shen, and Lucian V. Del Priore; Supervision: Lucian V. Del Priore.
Corresponding author
Ethics declarations
Conflicts of interest
No conflicting relationship exists for any author. Lucian V. Del Priore serves as a consultant for Astellas Institute for Regenerative Medicine.
Ethics approval
This study was exempted by the Yale Institutional Review Board.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Code availability
All study analyses were performed using R 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria).
Disclaimer
The sponsors or funding organizations had no role in the design or conduct of this research.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ahluwalia, A., Shen, L.L. & Del Priore, L.V. Central geographic atrophy vs. neovascular age–related macular degeneration: differences in longitudinal vision-related quality of life. Graefes Arch Clin Exp Ophthalmol 259, 307–316 (2021). https://doi.org/10.1007/s00417-020-04892-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-020-04892-5